Lorlatinib 25 mg, 50 mg,100 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 25 mg, 50 mg,100 mg

Reference Brands: Lorbrena (USA)

Category: Oncology Cancer Care

Lorlatinib is a Oncology Cancer Care product available as Tablets in strengths 25 mg, 50 mg,100 mg. It corresponds to the reference brand Lorbrena (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Lorlatinib, marketed under the brand names Lorbrena in the USA, Canada, and Japan, and Lorviqua in the European Union, is an oral anti-cancer medication used for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are ALK-positive. As a targeted therapy, Lorlatinib works as an inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), enzymes that are involved in cancer cell growth and proliferation. By blocking these kinases, Lorlatinib slows tumor progression and helps manage advanced lung cancer in patients who have developed resistance to prior ALK-targeted therapies.

Administered orally as a tablet, Lorlatinib is designed to provide systemic exposure to inhibit tumor activity while maintaining a manageable safety profile. It is particularly valuable for patients with metastatic NSCLC where standard chemotherapy and earlier-generation ALK inhibitors have failed. Lorlatinib has demonstrated efficacy in crossing the blood-brain barrier, addressing central nervous system metastases commonly observed in ALK-positive NSCLC. Approved in multiple regulated markets, Lorlatinib represents a critical treatment option for patients with advanced lung cancer, offering targeted therapy for improved clinical outcomes and disease management.